nCoV: Serological detection of past SARS-CoV-2 infection by non-invasive sampling for field epidemiology and quantitative antibody detection
Lead Research Organisation:
Imperial College London
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
Publications
Moshe M
(2021)
SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study.
in BMJ (Clinical research ed.)
Claudiani S
(2022)
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
in British journal of haematology
El Bouzidi K
(2021)
Severe Acute Respiratory Syndrome Coronavirus-2 Infections in Critical Care Staff: Beware the Risks Beyond the Bedside.
in Critical care medicine
Garson JA
(2022)
Highly sensitive and specific detection of the SARS-CoV-2 Delta variant by double-mismatch allele-specific real time reverse transcription PCR.
in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Clarke CL
(2021)
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection.
in Kidney international
Turner-Stokes T
(2021)
Serologic Screening for Coronavirus Disease 2019 in Patients With Glomerular Disease.
in Kidney international reports
Kitsou K
(2021)
Upregulation of Human Endogenous Retroviruses in Bronchoalveolar Lavage Fluid of COVID-19 Patients.
in Microbiology spectrum
Rosa A
(2021)
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity.
in Science advances
Thwaites RS
(2021)
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19.
in Science immunology
Khan M
(2022)
Simple, sensitive, specific self-sampling assay secures SARS-CoV-2 antibody signals in sero-prevalence and post-vaccine studies.
in Scientific reports
Houston H
(2022)
Broadening symptom criteria improves early case identification in SARS-CoV-2 contacts.
in The European respiratory journal
Harris BHL
(2021)
Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Rehabilitation Facility: Evolution of the Presence of Nasopharyngeal SARS-CoV-2 and Serological Antibody Responses.
in The Journal of infectious diseases
Pereira C
(2021)
The Association Between Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Post-COVID-19 Syndrome in Healthcare Workers.
in The Journal of infectious diseases
Tedder RS
(2021)
Appropriate selection of convalescent plasma donors for COVID-19.
in The Lancet. Infectious diseases
| Title | HYBRID DOUBLE ANTIGEN SARS-COV-2 ANTIBODY DETECTION ASSAY |
| Description | The present invention is directed to a method for detecting the presence or absence of SARS-Cov-2 antibodies in a sample, the method comprising: a. contacting the sample with a solid-phase support having a fusion protein immobilised thereto, said fusion protein comprising a first antigen and a scaffold polypeptide, 1. wherein the first antigen is a SARS-Cov-2 receptor binding domain polypeptide that binds anti-SARS-Cov-2 antibody, and ii. wherein the scaffold polypeptide immobilises the fusion protein to the solid-phase support and presents the first antigen away from the solid-phase support; b. allowing SARS-Cov-2 antibodies present in the sample to bind to the first antigen, thereby forming a complex of first antigen and SARS-Cov-2 antibody; c. contacting said complex with a labelled second antigen, wherein said labelled second antigen comprises a SARS-Cov-2 receptor binding domain polypeptide that binds SARS-Cov-2 antibody; d. allowing said labelled second antigen to bind to SARS-Cov-2 antibody present in the sample; e. removing labelled second antigen that is not bound to said complex; and f. detecting the presence of labelled second antigen bound to said complex; wherein the presence of labelled complex indicates the presence of SARS-Cov-2 antibody in the sample, and wherein the absence of labelled complex indicates the absence of SARS-Cov-2 antibody in the sample. |
| IP Reference | WO2022013574 |
| Protection | Patent application published |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | highest specificity and sensitivity, also predicts and measures neutralising antibody |